LYMEPOLICYWONK: Part 1–New Study Shows Lyme Persists in Monkeys

Byldoadmin

 

Before drilling down into the details in other posts,  let me give you the 10,000 foot elevation overview. The Embers study asks three important questions that are critical to understanding what is going on with Lyme disease.

Does the IDSA 28 day protocol for treating early disseminated Lyme disease (defined as 4 months after inoculation) eradicate Bb or does Bb persist notwithstanding short term treatment?

Answer:  Bb persisted in 100% of treated monkeys.  This suggests that at 4 months post infection 28 days of treatment with doxycycline may be insufficient to eradicate infection. (Persistent infection was demonstrated by other means including PCR, culture, immunofluorescence, and xenodiagnosis.)

Does the Klempner 90 day treatment protocol (30 days IV Rocephin, followed by 60 days oral doxycycline) for treating late disseminated Lyme disease (approximately 7 months after inoculation) eradicate Bb or does Bb persist notwithstanding this treatment?

Answer:  Bb persisted in approximately 75% of the infected monkeys. This suggests that different treatment approaches that are longer or involve different or combined antibiotics may be more appropriate when Lyme disease has been present for more than 6 months. The authors state: “[T]he use of variable and pulse-dosing regimens of antibiotics may improve efficacy [43] and this warrants testing in an appropriate model.”

Does the C6 antibody test accurately measure active infection?

Answer: The C6 antibody test detected active infection 100% of the time 27 weeks after inoculation for untreated monkeys. After 27 weeks, however, antibody response began returning to baseline and the test failed to detect active infection in approximately 60% of the untreated monkeys.  In addition, the antibody test failed to detect active infection in 100% of the treated monkeys.  This suggests that the C6 test is not sensitive enough to detect active disease in those who have had the disease for more than a few months or who in those who have been treated for the disease, but have persistent infection.

What is the take away message?  Lyme disease is hard to treat, may persist, and negative lab tests may not accurately reflect actual infection.

Because this study is so important, I am going to publish additional blog posts exploring in depth the implications of the study for chronic Lyme disease, early disseminated Lyme disease and diagnostic antibody testing.

Read additional parts of the series here:

Part 2–Treatment and Persistence

Part 3–IDSA 28-day treatment protocol fails to clear infection

Part 4–Lab tests fail to detect Lyme disease

Part 5–Of mice and men and monkeys

Read the journal article here.

References:

Embers ME, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, et al. Persistence of Borrelia burgdorferi in Rhesus Macaques following Antibiotic Treatment of Disseminated Infection. PLoS ONE. 2012;7(1):e29914. Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0029914.

Klempner M, Hu L, Evans J, Schmid C, Johnson G, Trevino R, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. The New England journal of medicine. 2001 Jul 12;345(2):85-92.

Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006 Nov 1;43(9):1089-134

The LYME POLICY WONK blog is written by Lorraine Johnson, JD, MBA, who is the Chief Executive Officer of LymeDisease.org, formerly CALDA. Contact her at lbjohnson@lymedisease.org.

Similar Posts

  • LYMEPOLICYWONK: IOM Report: ’Tis neither here nor there. Or?

    The Institute of Medicine (IOM) has released its long awaited report on Lyme disease. So should we celebrate or despair? I think there is room for a little of both. We should certainly celebrate the tone of the report, which characterizes the session as “a walk in the woods” to start dialogue and we should celebrate the contributions made by those who attended and participated, whether as patients, advocacy groups, researchers or physicians. I think these people did their very best to represent a side of Lyme disease that is not often given public voice. We should also recognize the contribution to a better process that was achieved by the three groups who pulled out of the hearing (CALDA, LDA, and Time for Lyme). This action resulted in Dr. Benjamin Luft of Stony Brook University being added to the agenda and may have also added to the “tone” of the report. What we should not lose sight of though, is that a civil tone and the inclusion of some patients’ testimony are not enough. This is a debate about science. Debates are about equal time, opportunities to rebut, and not excluding opposing viewpoints. That did not happen here. And, what the IOM left out or left unchallenged harms patients. Our biggest hits were in diagnosis, the exclusion of the topics chronic Lyme and treatment, and the complete exclusion of any physicians from ILADS. Let me drill down into the details.

  • LYMEPOLICYWONK: Lyme Physician Protection in Minnesota

    The Minnesota Board of Medical Practice (MBMP) has agreed to a five-year moratorium on the investigation, disciplining or issuance of corrective action based solely on long-term prescription or administration of antibiotic therapy for chronic Lyme disease. Minnesota joins a growing list of states that provide physician protection either through legislation or agreement, including California, Connecticut, Rhode Island, and New York. The MBMP took the action as a compromise to prevent pending physician protection legislation from passing. Any way you look at it, it was a good day for Lyme patients in Minnesota.

  • At the Gala

    Every now and then you gotta kick up your heels. This year I headed back east for Time for Lyme's GALA. The Young People's Chorus of New York City gave an amazing performance of internationally inspired songs. Actor, Director and Writer Lou Diamond Phillips of Lyme Life gave a compelling speech and a rousing performance singing with the band–including the song LA BAMBA–which had everyone up dancing. The picture is me leaning in to talk with Dr. Luc Montagnier, a Nobel Prize winner for his discovery of HIV, who was honored at the GALA.

  • LYMEPOLICYWONK: Institute of Medicine Cuts on the Bias for IDSA

    Finally, the Institute of Medicine (IOM) came out with its agenda for their “State of the Science Hearing”after much hemming and hawing. Patient groups (including CALDA) who asked for transparency in the study process received a mere “no comment” response. Well, we never got transparency, and we only got the agenda after it was finalized and released to the public. So, here’s the score: its 3 for 3 in the ‘Final Inning’ in favor of the IDSA.

    Four of the 6 IOM panel members are IDSA members.

    10 of the 14 physician speakers were authors on the IDSA guidelines or the copycat guidelines issued by members of the IDSA panel or members of the IDSA.

    Zero ILADS physicians have been chosen to speak. Let me repeat: ZERO, zip, nada, not a single ILADS physician was chosen to speak!

    Dr. Gary Wormser, poster boy of the Connecticut IDSA antitrust investigation, is kicking off the game.

    Oh, there’s window dressing to be sure. A personalized tour of the Agenda after the great leap forward. . .